Acute Graft Versus Host Disease: A Clinical Compendium on Answers to Clinicians’ Questions in Prevention and Management

To participate in this activity, please:

Bone marrow transplant specialist Nelson Chao, MD, dives into the topic of acute graft-versus-host disease (aGVHD), the most common complication after hematopoietic stem cell transplant (HSCT). Discussion surrounds the classification, diagnosis, severity, grading, and staging of aGVHD. He discusses recent guideline updates and recommended clinical management strategies for the prevention and treatment of patients with aGVHD and provides his insight into the current and emerging therapies undergoing evaluation in late-phase clinical trials. Finally, Dr. Chao highlights the burden of disease for patients, identifies patient resources and supportive measures, and provides his clinical perspective on the future management of patients with aGVHD.

Course Credit:

1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
0.5 Pharmacology Hours


Opens: 2023-03-27
Closes: 2024-03-27

Target Audience:

This activity was developed for hematologists, oncologists, physician assistants, nurse practitioners, nurses and all other healthcare professionals involved in the care of patients with graft-versus-host disease.

This activity is supported by an educational grant from CSL Behring.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour, including 0.5 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Amber Lambert, MSN, FNP-C, DNP (Nurse Planner)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Madison Saxton, PharmD, BCOP (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Nelson Chao, MD, MBA

    Donald D. and Elizabeth G. Cooke Professor
    Chief, Division of Hematologic Malignancies and Cellular Therapy/BMT
    Director, Duke Global Health Institute
    Duke University
    Durham, North Carolina

Learning Objectives

  • Classify the severity of acute graft-versus-host disease (aGVHD) according to recent grading and staging guidelines
  • Outline the pharmacologic therapies to treat aGVHD, including guideline recommendations for their use when available
  • Use best practice strategies for prevention and treatment of newly diagnosed aGVHD

Faculty Disclosures

Nelson Chao, MD, MBA

No relationships to disclose.